RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.


Scott Runyon

Director, Organic and Medicinal Chemistry


PhD, Medicinal Chemistry, Medical College of Virginia
BS, Chemistry, Muhlenberg College

Scott Runyon, Ph.D., is RTI’s principal investigator conducting synthetic medicinal chemistry research. Currently, his lab is developing small-molecule agonists for neuropeptide S and the APJ GPCR’s.

Since joining RTI in 2001, Dr. Runyon has focused on developing novel therapeutics, including:

  • Small-molecule kappa opioid antagonists
  • Dopamine transporter inhibitors
  • GABA allosteric modulators (neuroactive steroid scaffold)
  • Non-hormonal male contraceptives (indenopyridine scaffold)
  • Haptens and protein conjugates for nicotine and opiate vaccines
  • Orexin antagonists
  • Neurotensin modulators
  • Apelin and neuropeptide S peptide structure activity relationships
  • Small-molecule neuropeptide S agonists and antagonists
  • Small-molecule APJ/apelin agonists.

Dr. Runyon has extensive medicinal chemistry and drug development experience and has worked on teams, including, JDTic, a compound used to map the kappa opioid receptor. This project has progressed compounds to IND-ready and phase 1 clinical trials.  

Get in Touch

To speak to this expert or inquire about RTI services, you can reach us at +1 919 541 6000 or use the contact form below. For media inquiries, please reach out to our Media Relations team at news@rti.org.

Blue background circle graphics